Home > Publications database > An Ultra-Sensitive Assay For Diagnosis Of Alzheimer's Disease > print

001     62862
005     20200402210514.0
024 7 _ |2 pmid
|a pmid:18328004
024 7 _ |2 DOI
|a 10.1089/rej.2008.0670
024 7 _ |2 WOS
|a WOS:000255773200008
024 7 _ |a altmetric:21819147
|2 altmetric
037 _ _ |a PreJuSER-62862
041 _ _ |a eng
082 _ _ |a 610
084 _ _ |2 WoS
|a Geriatrics & Gerontology
100 1 _ |a Funke, S. A.
|b 0
|u FZJ
|0 P:(DE-Juel1)VDB65869
245 _ _ |a An Ultra-Sensitive Assay For Diagnosis Of Alzheimer's Disease
260 _ _ |a Larchmont, NY
|b Liebert
|c 2008
300 _ _ |a 315 - 318
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |a Rejuvenation Research
|x 1549-1684
|0 18202
|y 2
|v 11
500 _ _ |a Record converted from VDB: 12.11.2012
520 _ _ |a Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia. Aging is among the most significant risk factors. Today, AD can be diagnosed with certainty only post mortem, detecting insoluble beta-amyloid peptide (Abeta) aggregates in the patient's brain tissue. We have developed an ultrasensitive assay for early and non-invasive diagnosis of AD. This highly specific and sensitive assay uses fluorescence correlation spectroscopy (FCS) and is sensitive enough to detect even single aggregates in body fluids of AD patients. We investigate the correlation of aggregated Abeta concentrations in body fluids with clinical symptoms of AD.
536 _ _ |a Funktion und Dysfunktion des Nervensystems
|c P33
|2 G:(DE-HGF)
|0 G:(DE-Juel1)FUEK409
|x 0
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 2 |2 MeSH
|a Alzheimer Disease: diagnosis
650 _ 2 |2 MeSH
|a Amyloid beta-Peptides: cerebrospinal fluid
650 _ 2 |2 MeSH
|a Amyloid beta-Peptides: chemical synthesis
650 _ 2 |2 MeSH
|a Amyloid beta-Peptides: chemistry
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a Protein Structure, Quaternary
650 _ 2 |2 MeSH
|a Sensitivity and Specificity
650 _ 2 |2 MeSH
|a Spectrometry, Fluorescence: methods
650 _ 7 |0 0
|2 NLM Chemicals
|a Amyloid beta-Peptides
650 _ 7 |a J
|2 WoSType
700 1 _ |a Birkmann, E.
|b 1
|u FZJ
|0 P:(DE-Juel1)VDB65870
700 1 _ |a Henke, F.
|b 2
|0 P:(DE-HGF)0
700 1 _ |a Görtz, P.
|b 3
|0 P:(DE-HGF)0
700 1 _ |a Lange-Asschenfeldt, C.
|b 4
|0 P:(DE-HGF)0
700 1 _ |a Riesner, D.
|b 5
|0 P:(DE-HGF)0
700 1 _ |a Willbold, D.
|b 6
|u FZJ
|0 P:(DE-Juel1)132029
773 _ _ |a 10.1089/rej.2008.0670
|g Vol. 11, p. 315 - 318
|p 315 - 318
|q 11<315 - 318
|0 PERI:(DE-600)2155984-3
|t Rejuvenation research
|v 11
|y 2008
|x 1549-1684
856 7 _ |u http://dx.doi.org/10.1089/rej.2008.0670
909 C O |o oai:juser.fz-juelich.de:62862
|p VDB
913 1 _ |k P33
|v Funktion und Dysfunktion des Nervensystems
|l Funktion und Dysfunktion des Nervensystems
|b Gesundheit
|0 G:(DE-Juel1)FUEK409
|x 0
914 1 _ |y 2008
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |k INB-2
|l Molekulare Biophysik
|d 31.12.2008
|g INB
|0 I:(DE-Juel1)VDB805
|x 0
970 _ _ |a VDB:(DE-Juel1)99745
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)ISB-2-20090406
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
981 _ _ |a I:(DE-Juel1)IBI-7-20200312
981 _ _ |a I:(DE-Juel1)ISB-2-20090406
981 _ _ |a I:(DE-Juel1)ICS-6-20110106

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21